Cargando…
A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
BACKGROUND: The advent of immune checkpoint inhibitors (ICIs) has considerably expanded the armamentarium against non-small cell lung cancer (NSCLC) contributing to reshaping treatment paradigms in the advanced disease setting. While promising tissue- and plasma-based biomarkers are under investigat...
Autores principales: | Botticelli, Andrea, Salati, Massimiliano, Di Pietro, Francesca Romana, Strigari, Lidia, Cerbelli, Bruna, Zizzari, Ilaria Grazia, Giusti, Raffaele, Mazzotta, Marco, Mazzuca, Federica, Roberto, Michela, Vici, Patrizia, Pizzuti, Laura, Nuti, Marianna, Marchetti, Paolo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437908/ https://www.ncbi.nlm.nih.gov/pubmed/30917841 http://dx.doi.org/10.1186/s12967-019-1847-x |
Ejemplares similares
-
Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
por: Botticelli, Andrea, et al.
Publicado: (2018) -
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
por: Botticelli, Andrea, et al.
Publicado: (2017) -
The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial
por: Botticelli, Andrea, et al.
Publicado: (2020) -
Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1
por: Botticelli, Andrea, et al.
Publicado: (2020) -
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy
por: Botticelli, Andrea, et al.
Publicado: (2020)